MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Zacks01-03

Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGVHD)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500141989?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-03 23:56","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2500141989","market":"us","top_or_hot":-1,"title":"MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug","media":"Zacks","content":"<div>\n<p>Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGVHD)...</p>\n\n<a href=\"https://finance.yahoo.com/news/meso-stock-surges-80-month-155600622.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-03 23:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/meso-stock-surges-80-month-155600622.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGVHD)...</p>\n\n<a href=\"https://finance.yahoo.com/news/meso-stock-surges-80-month-155600622.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/meso-stock-surges-80-month-155600622.html","article_id":"2500141989","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500141989","pubTimestamp":1735919760,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only approved therapy for steroid-refractory acute graft versus host disease  in children aged two months and older, including adolescents and teenagers. The drug has a novel mechanism of action and will be marketed under the brand name Ryoncil in the United States.The approval gave Mesoblast its first approved product in its portfolio. Sales of the drug are expected to provide the company with a steady source of income. The company is currently gearing up to launch the product in the U.S. market.SR-aGVHD is a devastating condition that has an extremely poor prognosis. Each year in the United States, around 10,000 patients, including 1,500 children, undergo allogeneic bone marrow transplants. About 50% develop aGvHD, and nearly half of these cases are steroid-resistant.In the past six months, shares of Mesoblast have skyrocketed 202.9% against the industry’s 4.8% decline.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SPRO":"Spero Therapeutics Inc.","CSTL":"Castle Biosciences, Inc.","CTMX":"CytomX","BK4196":"保健护理服务","MSB.AU":"MESOBLAST LTD","MESO":"Mesoblast Limited"},"translate_title":"FDA批准GVHD药物后，MESO股价一个月内飙升80%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTMX":1,"MESO":1,"SPRO":1,"CSTL":0.9,"MSB.AU":0.9},"content_text":"Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGVHD) in children aged two months and older, including adolescents and teenagers. The drug has a novel mechanism of action and will be marketed under the brand name Ryoncil in the United States.\nThe approval gave Mesoblast its first approved product in its portfolio. Sales of the drug are expected to provide the company with a steady source of income. The company is currently gearing up to launch the product in the U.S. market.\nSR-aGVHD is a devastating condition that has an extremely poor prognosis. Each year in the United States, around 10,000 patients, including 1,500 children, undergo allogeneic bone marrow transplants. About 50% develop aGvHD, and nearly half of these cases are steroid-resistant.\nIn the past six months, shares of Mesoblast have skyrocketed 202.9% against the industry’s 4.8% decline.\nImage Source: Zacks Investment Research\nThe FDA approval was based on positive results from a phase III study of remestemcel-L in children with SR-aGvHD, 89% of whom had high-severity Grade C or Grade D disease. Among the patients treated with the drug, 70% achieved an overall response by Day 28, a measure that predicts survival in aGVHD.\nFurthermore, no patient had their Ryoncil treatment discontinued or interrupted due to any laboratory abnormality, and more than 85% of patients completed the full course without interruption.\nMesoblast is also looking to expand Ryoncil’s label to include the treatment of adult patients with SR-aGVHD. A late-stage study is currently evaluating the drug in this patient population. Additionally, the company is also evaluating Ryoncil in a mid-stage study for certain inflammatory bowel disease indications: ulcerative colitis and Crohn’s colitis.\nOther Clinical Programs in MESO’s Pipeline\nMesoblast has another late-stage pipeline candidate, rexlemestrocel-L, which is being developed for heart failure and chronic low back pain (CLBP).\nIn March 2024, MESO announced that the FDA supports an accelerated approval pathway for rexlemestrocel-L in patients with end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device. The company plans to hold a meeting with the FDA to discuss the next steps in filing for the candidate for the HFrEF indication in children and adults. A potential approval will further strengthen Mesoblast’s commercial portfolio and form another source of revenue generation.\nIn July 2024, Mesoblast initiated patient enrollment in its late-stage study of rexlemestrocel-L in patients with CLBP due to inflammatory degenerative disc disease of less than five years duration. The company had previously reached alignment with the FDA regarding the CLBP study design. The primary endpoint of the study is pain reduction after 12 months of treatment. Key secondary endpoints include improvement in quality of life, function and reduced opioid usage.\n\nMesoblast Limited Price and Consensus\n\nMesoblast Limited price-consensus-chart | Mesoblast Limited Quote\n\nMESO’s Zacks Rank & Other Stocks to Consider\nMesoblast currently carries a Zacks Rank #2 (Buy).\nSome other top-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX and Spero Therapeutics SPRO. While CSTL and SPRO sport a Zacks Rank #1 (Strong Buy) each, CTMX carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, 2024 estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In one month, shares of Castle Biosciences have lost 12%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In one month, Spero’s shares have lost 8.5%.\nSPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.\nIn the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. In one month, CTMX stock has lost 17.8%.\nCytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nMesoblast Limited (MESO) : Free Stock Analysis Report\nCytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500141989"}